Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period

Clinical Microbiology and Infection

Volumn 16, Issue 5, 2010, Pages 402-410

  Linares J ^a,b   Ardanuy, C ^b   Pallares, R ^a   Fenoll, A ^c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Genotypes; Penicillin resistant; Review; Serotypes; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BACTERIAL PROTEIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; LINCOSAMIDE DERIVATIVE; MACROLIDE; MIKAMYCIN B; MOXIFLOXACIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; PROTEIN ERMB; PROTEIN MEFA; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SURVEILLANCE; DRUG USE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC DISEASE; TREND STUDY; UNITED STATES; VACCINATION;

STREPTOCOCCUS PNEUMONIAE;

EID: 77952906140     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03182.x     Document Type: Review

References (82)

1. Hansman D, Bullen MM. A resistant pneumococcus. Lancet 1967, 277:264-265.
2. Hansman D, Devitt L, Miles H, Riley I. Pneumococci relatively insensitive to penicillin in Australia and New Guinea. Med J Aust 1974, ii:353-356.
3. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990, 3:171-196.
4. Jacobs MR, Koornhof HJ, Robins-Browne RM. Emergence of multiply resistant pneumococci. N Engl J Med 1978, 299:735-740.
5. Liñares J, Garau J, Domínguez C, Pérez JL. Antibiotic resistance and serotypes of Streptococcus pneumoniae from patients with community-acquired pneumococcal disease. Antimicrob Agents Chemother 1983, 23:545-547.
6. Appelbaum PC. World-wide development of antibiotic resistance in pneumococci. Eur J Clin Microbiol 1987, 6:367-377.
7. Michel J, Dickman D, Greenberg Z, Bergner-Rabinowitz S. Serotype distribution of penicillin-resistant pneumococci and their susceptibilities to seven antimicrobial agents. Antimicrob Agents Chemother 1983, 23:397-401.
8. Fenoll A, Martin Bourgon C, Munoz R. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev Infect Dis 1991, 13:56-60.
9. Liñares J, Pallares R, Alonso T. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin Infect Dis 1992, 15:99-105.
10. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992, 15:77-83.
11. Low DE. Changing trends in antimicrobial-resistant pneumococci: it's not all bad news. Clin Infect Dis 2005, 41(suppl 4):S228-S233.
12. Goossens H, Ferech M, Coenen S, Stephens P. European Surveillance of Antimicrobial Consumption Project Group. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. Clin Infect Dis 2007, 44:1091-1095.
13. Kyaw MH, Lynfield R, Schaffner W. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006, 354:1455-1463.
14. Pilishvili T, Lexau C, Farley MM. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
15. Aguiar SI, Serrano I, Pinto FR, Melo-Cristino J, Ramirez M. Portuguese Surveillance Group for the Study of Respiratory Pathogens. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 2008, 14:835-843.
16. Fenoll A, Granizo JJ, Aguilar L. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 2009, 47:1012-1020.
17. Moore MR, Gertz RE, Woodbury RL. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008, 197:1016-1027.
18. Ardanuy C, Rolo D, Fenoll A, Tarrago D, Calatayud L, Liñares J. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J Antimicrob Chemother 2009, 64:507-510.
19. Choi EH, Kim SH, Eun BW. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008, 14:275-281.
20. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 2009, 199:776-785.
21. Mahjoub-Messai F, Doit C, Koeck JL. Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal vaccination for French children. J Clin Microbiol 2009, 47:837-840.
22. Aguiar SI, Pinto FR, Nunes S. Increase of Denmark14-230 clone as a cause of pneumococcal infection in Portugal within a background of diverse serotype 19A lineages. J Clin Microbiol 2010, 48:101-108.
23. Hackenbeck R, Ellerbrok H, Briese T. Penicillin-binding proteins of penicillin-susceptible and -resistant pneumococci: immunological relatedness of altered proteins and changes in peptides carrying the β-lactam binding site. Antimicrob Agents Chemother 1986, 30:553-558.
24. Liñares J, Alonso T, Pérez JL. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics. J Antimicrob Chemother 1992, 30:279-288.
25. Pallares R, Gudiol F, Liñares J. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med 1987, 317:18-22.
26. Pallares R, Linares J, Vadillo M. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995, 333:474-480.
27. Pallares R, Capdevila O, Liñares J. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am J Med 2002, 113:120-126.
28. Friedland IR, Klugman KP. Antibiotic-resistant pneumococcal disease in South African children. Am J Dis Child 1992, 146:920-923.
29. Yu VL, Chiou CC, Feldman C. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003, 37:230-237.
30. Song JH, Jung SI, Ko KS. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004, 48:2101-2107.
31. Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009, 48:1596-1600.
32. Performance standards for antimicrobial susceptibility testing: Eighteenth Informational Supplement. M100-S18 2008, Wayne, PA, CLSI
33. Spika JS, Facklam RR, Plikaytis BD. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group. J Infect Dis 1991, 163:1273-1278.
34. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis 1996, 174:986-993.
35. Geographic variation in penicillin resistance in Streptococcus pneumoniae-selected sites, United States, 1997. MMWR 1999, 48:656-661.
36. Felmingham D, White AR, Jacobs MR. The Alexander Project: the benefits from a decade of surveillance. J Antimicrob Chemother 2005, 56(suppl 2):ii3-ii21.
37. Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob 2008, 7:1-11.
38. Felmingham D, Cantón R, Jenkins SG. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 2007, 55:111-118.
39. Castanheira M, Gales AC, Mendes RE, Jones RN, Sader HS. Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program. Clin Microbiol Infect 2004, 10:645-651.
40. Borg MA, Tiemersma E, Scicluna E. ARMed Project members and collaborators. Prevalence of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae isolates reported by laboratories in the southern and eastern Mediterranean region. Clin Microbiol Infect 2009, 15:232-237.
41. EARSS Annual Report 2008. http://www.rivm.nl/earss/Images/EARSS%202008_final_tcm61-65020.pdf, Available at: (last accessed 26 November 2009
42. Doern GV, Heilmann KP, Huynh HK. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001, 45:1721-1729.
43. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009, 48:e23-e33.
44. van der Linden M, Al-Lahham A, Haupts S, Reinert RR. Clonal spread of mef-positive macrolide-resistant Streptococcus pneumoniae isolates causing invasive disease in adults in Germany. Antimicrob Agents Chemother 2007, 51:1830-1834.
45. Amezaga MR, Carter PE, Cash P, McKenzie H. Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites. J Clin Microbiol 2002, 40:3313-3318.
46. Littauer P, Sangvik M, Caugant DA, Høiby EA, Simonsen GS, Sundsfjord A. Norwegian Macrolide Study Group. Molecular epidemiology of macrolide-resistant isolates of Streptococcus pneumoniae collected from blood and respiratory specimens in Norway. J Clin Microbiol 2005, 43:2125-2132.
47. Van Eldere J, Meekers E, Lagrou K. Macrolide-resistance mechanisms in Streptococcus pneumoniae isolates from Belgium. Clin Microbiol Infect 2005, 11:332-334.
48. Monaco M, Camilli R, D'Ambrosio F, Del Grosso M, Pantosti A. Evolution of erythromycin resistance in Streptococcus pneumoniae in Italy. J Antimicrob Chemother 2005, 55:256-259.
49. Reinert RR, Ringelstein A, van der Linden M, Cil MY, Al-Lahham A, Schmitz FJ. Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe. J Clin Microbiol 2005, 43:1294-1300.
50. Siira L, Rantala M, Jalava J. Temporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae isolates in Finland, 2002 to 2006. Antimicrob Agents Chemother 2009, 53:2066-2073.
51. Calatayud L, Ardanuy C, Cercenado E. Serotypes, clones, and mechanisms of resistance of erythromycin-resistant Streptococcus pneumoniae isolates collected in Spain. Antimicrob Agents Chemother 2007, 51:3240-3246.
52. Reinert RR, Filimonova OY, Al-Lahham A. Mechanisms of macrolide resistance among Streptococcus pneumoniae isolates from Russia. Antimicrob Agents Chemother 2008, 52:2260-2262.
53. Bae S, Lee K. Distribution of capsular serotypes and macrolide resistance mechanisms among macrolide-resistant Streptococcus pneumoniae isolates in Korea. Diagn Microbiol Infect Dis 2009, 63:213-216.
54. Isozumi R, Ito Y, Ishida T. Genotypes and related factors reflecting macrolide resistance in pneumococcal pneumonia infections in Japan. J Clin Microbiol 2007, 45:1440-1446.
55. Song JH, Chang HH, Suh JY. Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP). J Antimicrob Chemother 2004, 53:457-463.
56. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 2009, 15:1260-1264.
57. Wierzbowski AK, Nichol K, Laing N. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998-2004). J Antimicrob Chemother 2007, 60:733-740.
58. Wolter N, von Gottberg A, du Plessis M, de Gouveia L, Klugman KP. Group for Enteric, Respiratory Meningeal Disease Surveillance in South Africa Molecular basis and clonal nature of increasing pneumococcal macrolide resistance in South Africa, 2000-2005. Int J Antimicrob Agents 2008, 32:62-67.
59. Farrell DJ, Jenkins SG, Brown SD, Patel M, Lavin BS, Klugman KP. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis 2005, 11:851-858.
60. Del Grosso M, Northwood JG, Farrell DJ, Pantosti A. The macrolide resistance genes erm(B) and mef(E) are carried by Tn2010 in dual-gene Streptococcus pneumoniae isolates belonging to clonal complex CC271. Antimicrob Agents Chemother 2007, 51:4184-4186.
61. Buu-Hoï AY, Goldstein FW, Acar JF. A seventeen-year epidemiological survey of antimicrobial resistance in pneumococci in two hospitals. J Antimicrob Chemother 1988, 22(suppl B):41-52.
62. Doern GV, Brown SD. Antimicrobial susceptibility among community acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 2004, 48:56-65.
63. Pérez-Trallero E, Fernández-Mazarrasa C, García-Rey C. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001, 45:3334-3340.
64. Whitney CG, Farley MM, Hadler J. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000, 343:1917-1924.
65. Lonks JR, Garau J, Gomez L. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002, 35:556-564.
66. Marimón JM, Iglesias L, Vicente D, Pérez-Trallero E. Molecular characterization of erythromycin-resistant clinical isolates of the four major antimicrobial-resistant Spanish clones of Streptococcus pneumoniae (Spain23F-1, Spain6B-2, Spain9V-3, and Spain14-5). Microb Drug Resist 2003, 9:133-137.
67. Muñoz R, De La Campa AG. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother 1996, 40:2252-2257.
68. de la Campa AG, Balsalobre L, Ardanuy C, Fenoll A, Pérez-Trallero E, Liñares J. Spanish Pneumococcal Infection Study Network G03/103. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain. Emerg Infect Dis 2004, 10:1751-1759.
69. de la Campa AG, Ardanuy C, Balsalobre L. Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg Infect Dis 2009, 15:905-911.
70. Chen DK, McGeer A, De Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999, 341:233-239.
71. Liñares J, de la Campa AG, Pallares R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999, 341:1546-1547.
72. Riedel S, Beekmann SE, Heilmann KP. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2007, 26:485-490.
73. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005, 41:118-121.
74. Adam HJ, Hoban DJ, Gin AS, Zhanel GG. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int J Antimicrob Agents 2009, 34:82-85.
75. Carratalá J, Martín-Herrero JE, Mykietiuk A, García-Rey C. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones. Clin Microbiol Infect 2006, 12(suppl 3):2-11.
76. Schurek KN, Adam HJ, Siemens CG, Hoban CJ, Hoban DJ, Zhanel GG. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003. J Antimicrob Chemother 2005, 56:769-772.
77. McGee L, McDougal L, Zhou J. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol 2001, 39:2565-2571.
78. Ardanuy C, Tubau F, Pallares R. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis 2009, 48:57-64.
79. Zhou J, Enright MC, Spratt BG. Identification of the major Spanish clones of penicillin-resistant pneumococci via the Internet using multilocus sequence typing. J Clin Microbiol 2000, 38:977-986.
80. Fotopoulou N, Tassios PT, Beste DV. A common clone of erythromycin-resistant Streptococcus pneumoniae in Greece and the UK. Clin Microbiol Infect 2003, 9:924-929.
81. McEllistrem MC, Adams JM, Shutt K. Erythromycin-nonsusceptible Streptococcus pneumoniae in children, 1999-2001. Emerg Infect Dis 2005, 11:969-972.
82. Gertz RE, McEllistrem MC, Boxrud DJ. Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. J Clin Microbiol 2003, 41:4194-4216.